


Quarterly Round Up

One Step Forward,
Q2 Steps Back




M&A

After a strong start to the year, the second quarter saw a significant decline.




Top 3 Deals in Q2




VC Investment

VC investment surges as financial market recovery momentum builds. Earlier-stage companies appear to be getting in on the fundraising action as 2024 progresses.




Top Financing Rounds in Q2



IPOs

Biotechs have had a tough time raising cash through flotations, with one stepping away altogether.



The situation is worse in Europe. The last biotech to list on a European stock exchange was in February 2022.



▶ **DOWNLOAD THE FULL QUARTERLY ROUND UP REPORT HERE**